Day: July 22, 2021

KURI – Peer-reviewed Research Finds Babylon's Digital-first Model Of Primary Care Is Associated With Lower Significantly NHS Hospital Care Costs

LONDON, July 22, 2021 /PRNewswire/ — Researchers at Babylon, a leading digital-first value-based healthcare company,  have found that members of Babylon’s highly accessible, 24/7 primary care model incurred between 15-35% lower acute hospital costs than the regional average.

Babylon GP at Hand is a digital-first NHS GP practice, free at the point of need for members. Over 80% of appointments are virtual, which members can access at any time of day or night, 365 days per year. Every member has access to a full suite of self-care technology, including symptom checking, digital health assessment and digital twin avatars as well as virtual and in-person consultations. Over 100,000 people across London and Birmingham have registered with Babylon GP at Hand since November 2017.

Dr Sam Winward, lead author, said “This work shows that the Babylon model of highly accessible, digital-first primary care is associated with significantly lower downstream costs. The findings were observed after adjusting for healthcare needs, meaning they do not simply reflect the fact that Babylon members were typically younger than the comparator group. The savings in secondary care significantly outweigh the additional investment required to provide the Babylon model of primary care, making it an important proof point for our global mission, to provide an accessible, affordable health service to every person on earth.”

The peer-reviewed research titled ‘The effect of 24/7, digital-first NHS primary care on acute hospital spend: a retrospective, observational analysis‘ published in JMIR, compared the spend per patient at the Babylon GP at Hand practice to all other practices in the North West London region. Lower costs were seen over two consecutive years, during which time the registered population of Babylon GP at Hand doubled in size, demonstrating that the effect is scalable. The work builds on findings from an independent NHS evaluation of Babylon GP at Hand, which reported that members were significantly less likely to use certain emergency services after registering with Babylon GP at Hand.

Ali Parsa, CEO of Babylon, said: “The triple-aim of healthcare has long been clear – to improve the patient experience of care; to improve the health of populations; and to reduce the per capita cost of healthcare. Preventative healthcare is now understood to be the key to unlocking these benefits, but all too often general practices are not resourced or able to provide the accessibility of high quality care required. As a result, primary care clinicians burn out, costs bankrupt people and patient populations are not well served. Babylon has invested in accessibility, in technology and in supporting staff, with the deliberate aim of solving more of our members’ problems in primary care. It’s great to see further evidence that our end-to-end digital-first services are benefiting patients and doctors by solving patient health problems and reducing expensive downstream care,  through accessible and clinically effective primary care.”.

Darshak Sanhavi, CMO of Babylon and former group director of CMS during the Obama administration, added: “This is powerful evidence that by improving access through digital-first healthcare can lead to meaningful reduction on downstream care costs. This is a lesson that can apply outside the UK into markets like the US, Canada, and beyond.”

Some of Babylon’s digital-first healthcare services are already available at the Royal Wolverhampton NHS Trust Wolverhampton and University Hospitals Birmingham NHS Foundation Trust, reaching over 1.5 million patients. Both NHS Trusts partnered with Babylon to use the app-based service to help flag patients with potential coronavirus, as well as assist those who have been diagnosed with coronavirus to address their medical needs.

Notes to Editors

About Babylon

Babylon is a world leading, digital-first, value-based care company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth.

Babylon is reengineering healthcare, shifting the focus from sick care to preventative healthcare so that patients experience better health, and reduced costs. This is achieved by leveraging a highly scalable, digital-first platform combined with high quality, virtual clinical services to provide all-in-one healthcare. We endeavour to keep patients at the peak of health and get them back on their feet as quickly as possible, all from their devices, with the aim to promote longer and healthier lives. When sick, Babylon provides assistance to navigate the health system, connecting patients digitally to the right clinician 24/7, at no additional cost.

Founded in 2013, we have since delivered millions of clinical consultations and AI interactions, with c.2m clinical consultations and c.3.9m AI interactions in 2020 alone. We work with governments, health providers and insurers across the globe, and support healthcare facilities from small local practices to large hospitals.

On June 3 2021, Babylon announced its plans to become a public company via a merger with Alkuri Global Acquisition Corp. (NASDAQ:KURI), a special purpose acquisition company. Upon closing of the transaction, the combined company will operate as Babylon and plans to trade on Nasdaq under the new symbol “BBLN”. The transaction reflects an initial pro forma equity value of approximately $4.2 billion. The transaction is expected to close in the second half of 2021.

For more information, please visit www.babylonhealth.com/us.

About the research

The paper, titled The effect of 24/7, digital-first NHS primary care on acute hospital spend: a retrospective, observational analysis” and authored by Winward S et al. will be published in JMIR and available from 22 July 06 am GMT.

Acute hospital spending for each practice was obtained through a freedom of information request; no patient-identifiable information was accessed or used. Each practice population was adjusted for healthcare need, using standard NHS methods, therefore removing any difference in spending that may arise due to the difference in populations, such as patients being younger. Three NHS methods were used to adjust for healthcare need, hence the range of percentages quoted in the findings. Although the study found 51% lower spending using the Carr-Hill weighting methodology, our quoted central finding is 15-35%. The Carr-Hill weighting takes into account demographics and other drivers of need, but is designed to determine primary funding / spend, which will not fully reflect acute care spend. This weighting approach was recommended in the FOI response and UK readers may expect to see it, hence it was included in the research and used as a cross check but not quoted in the central 15-35% finding.

North West London is used as the comparator as the Babylon GP at Hand practice is located in this area. Hospital spend across GP practices with different demographics and locations is compared by using the cost per weighted patient. Patient weightings are used by the NHS to ensure fair allocation of resources.

The NHS-commissioned independent evaluation of Babylon GP at Hand reported the likelihood of a patient attending Accident and Emergency for each of the 12 months before and after joining Babylon GP at Hand. The 28% difference reported is the difference between the average for the 12 months before and the 12 months after joining. For the full report, please see here.

Media contact: Stina Sanders, [email protected]

SOURCE Babylon

Related Links

https://www.babylonhealth.com/us

VGANF – Plant&Co Confirms Annual General and Special Meeting

Toronto, Ontario–(Newsfile Corp. – July 22, 2021) – Plant&Co. Brands Ltd. (CSE: VEGN) (FSE: VGP) (OTCQB: VGANF) (“Plant&Co” or the “Company“), a modern health and wellness company curating delicious plant-based foods, is pleased to announce that, further to its news release of April 13, 2021, it has set the date for its annual general and special meeting (the “Meeting“) wherein the Company will seek shareholder (the “Plant&Co Shareholders“) approval to certain resolutions, including a special resolution (the “Arrangement Resolution“) to approve the proposed plan of arrangement (the “Arrangement“) pursuant to Division 5 of Part 9 of the Business Corporations Act (British Columbia) with 1309185 BC Ltd. (“Spinco“).

The Meeting will be held on September 2, 2021, at the Company’s registered office located at Suite 400, 1681 Chestnut Street, Vancouver, British Columbia. The record date (as it pertains to voting rights and shareholder dividend stock) for the Meeting has been set as July 22, 2021.

In order for the Arrangement to become effective, the Arrangement Resolution must be passed, with or without variation, by a special resolution of at least 66.66% of the eligible votes cast in respect of the Arrangement Resolution by the Plant&Co Shareholders present in person or by proxy at the Meeting.

The purpose of the Arrangement is to allow the Company to divest itself of its cannabis related assets (the “Assets“) to Spinco, enabling the Company to remain strategically focused on its plant-based food technology. Spinco will have a diversified management team, with special focus on emerging technologies.

Following completion of the Arrangement:

  1. Spinco will continue to hold the Assets transferred to it by Plant&Co,
  2. Spinco will become a reporting issuer in the Provinces of British Columbia, Alberta and Ontario, and intends to apply for listing on the Canadian Securities Exchange (the “Exchange“),
  3. each Plant&Co Shareholder will continue to be a Plant&Co Shareholder,
  4. each Plant&Co Shareholder will become a shareholder of Spinco, and
  5. Plant&Co will retain its working capital for its Assets, remain listed on the Exchange and will continue to trade under the trading symbol, VEGN.

Plant&Co. will retain a framework of its technology to continue its digital growth of assets in the food and plant-based sector.

Further details will be provided following execution of the arrangement agreement.

About Plant&Co

Plant&Co. Brands Ltd. (CSE: VEGN) (FSE: VGP) (OTCQB: VGANF) is modern health and wellness company curating delicious plant-based foods. It offers a growing number of delicious plant-based food products through two leading plant-based brands Holy Crap Foods Inc. and YamChops, the vegan butcher. For more information please visit: www.HolyCrap.com www.YamChops.com www.PlantandCo.com.

For additional information, please contact:

Shawn Moniz
Chief Executive Officer
Plant & Co. Brands Ltd.
ir@plantandco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur, and include the Company’s intention to complete the plan of arrangement to allow it to divest its cannabis related assets, as well as the impact that such a divestment would have on the Company and Spinco. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Plant&Co. Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90928

info

IBM – Amadeus Integrates IBM Digital Health Pass Into Its Digital Health Verification Technology

Integration is designed to help streamline the validation of air travelers’ COVID-19 health
documentation, reducing friction during check-in, and supporting airlines as the industry works to
increase international travel volumes

ARMONK, N.Y. and MADRID, July 22, 2021 /PRNewswire/ — IBM (NYSE: IBM) and Amadeus (MCE: AMS) today announced that they are working together to help meet one of the major challenges facing travel companies today: checking and validating the COVID-19 health documentation of travelers at checkpoints where required.

As part of that effort, IBM Digital Health Pass is now integrated into Traveler ID for Safe Travel, Amadeus’ digital health verification solution. This enables airlines to integrate the use of COVID-19 digital health credentials into their existing reservation and booking system, allowing airline passengers the option to scan or upload documentation to show their health credentials.

As passengers move through the online check-in process, Traveler ID for Safe Travel checks the requirements for that particular trip against destination country regulations. This then prompts passengers with the option to generate a secure COVID-19 digital credential by scanning paper documents or uploading a digital version from their mobile or desktop.

These COVID-19 digital health credentials are then verified using IBM Digital Health Pass, which uses a combination of encryption and blockchain technologies to authenticate COVID-19 health credentials against a global ecosystem of labs, vaccination centers and healthcare providers. Airlines receive a simple status confirming a passenger is ready to fly. This secure approach provides passenger privacy since only the compliance with border entry requirements is confirmed; no personal health information is stored by the airline, IBM, or Amadeus.

“While countries across the globe are beginning to slowly reopen borders to welcome back visitors, specific border entry requirements may vary greatly country to country. The need to check COVID-19 health documentation is causing significant delays during the journey for airlines and other travel providers, as well as the traveler,” said Greg Land, Travel and Transportation Industry Lead, IBM. “The integration of IBM Digital Health Pass into Amadeus’ Traveler ID for Safe Travel is designed to provide airlines with open technologies they can build into existing digital solutions. This can help airlines safely meet border entry requirements while delivering a smoother customer experience.”

“The integration with IBM is a step-change for Traveler ID for Safe Travel. The combination of the IBM Digital Health Pass with our Traveler ID for Safe Travel technology means that COVID-19 health documents can be digitized and read, verified, and authenticated. This avoids cumbersome and time-consuming checks while traveling, and adds further reassurance to airlines and their passengers,” said Christian Warneck, VP Safe Travel Ecosystem, Amadeus. “This is another milestone in the collaboration we are driving through our Safe Travel Ecosystem. By working hand in hand with customers and partners such as IBM, we can deliver the capabilities needed by travel providers and travelers to help provide a smooth passenger journey once more.”

Traveler ID for Safe Travel is currently live with multiple airlines, with additional airline customers to be announced soon. Traveler ID’s digital identity and health verification capabilities are also relevant for other customer groups, including hotels and airports. 

About IBM
For more information about IBM visit, www.ibm.com.

IBM’s statements regarding its plans, directions, and intent are subject to change or withdrawal without notice at IBM’s sole discretion. Information regarding potential future products is intended to outline our general product direction and it should not be relied on in making a purchasing decision. The information mentioned regarding potential future products is not a commitment, promise, or legal obligation to deliver any material, code or functionality. Information about potential future products may not be incorporated into any contract. The development, release, and timing of any future features or functionality described for our products remains at our sole discretion.

About Amadeus 
Travel powers progress. Amadeus powers travel. Amadeus’ solutions connect travelers to the journeys they want through travel agents, search engines, tour operators, airlines, airports, hotels, cars and railways. We have developed our technology in partnership with the travel industry for over 30 years. We combine a deep understanding of how people travel with the ability to design and deliver the most complex, trusted, critical systems our customers need. We help connect over 1.6 billion people a year to local travel providers in over 190 countries. We are one company, with a global mindset and a local presence wherever our customers need us. Our purpose is to shape the future of travel. We are passionate in our pursuit of better technology that makes better journeys. 

Amadeus is an IBEX 35 company, listed on the Spanish Stock Exchange under AMS.MC. The company is also part of the EuroStoxx50 and has been recognized by the Dow Jones Sustainability Index for the last eight years. 

To find out more about Amadeus, visit www.amadeus.com.  

Media Contacts
Allison Bishop
(717) 572-3309
[email protected]

Laura Cobbold
+34 609141695
[email protected]

SOURCE IBM

Related Links

www.ibm.com